Who is ... Christoph Kreer?

“What fascinates me most about science is discovering common principles across systems that, at first glance, seem completely unrelated.”
PD Dr. Christoph Kreer is a biochemist and molecular life scientist who leads a research group at the Institute of Virology at the University of Cologne and University Hospital Cologne. His research examines how antibody responses adapt to evolving pathogens and how pathogens, in turn, evade immune recognition. By working at the interface of molecular immunology, virology, and bioinformatics, his group aims to identify principles that can inform future vaccines and antibody-based interventions.
Research Focus
A central theme of Kreer’s research is the reciprocal relationship between B-cell immunity and pathogen evolution. Following infection or vaccination, B cells generate highly diverse antibodies and establish immunological memory, while rapidly evolving pathogens can evade this protection through antigenic variation.
Kreer investigates how B-cell selection, immunodominance, and immune imprinting shape antibody responses to changing antigens, and which molecular constraints determine how pathogens can evolve under immune pressure. His work focuses particularly on clinically relevant respiratory viruses, including influenza viruses and coronaviruses.
His group combines advanced B-cell receptor repertoire analysis, isolation and functional characterization of monoclonal antibodies, molecular analysis of viral antigens, high-throughput technologies, and computational approaches. Integrating antibody- and antigen-centered perspectives, Kreer seeks to identify principles of immune escape and vulnerable antigenic targets for future preventive and therapeutic strategies.
Read more ...
Selected Publications & Scientific Contributions
Kreer has contributed to the development of technologies for high-throughput analysis of human B-cell responses and the identification of potent monoclonal antibodies. During the COVID-19 pandemic, he was first author of a study published in Cell describing highly potent human neutralizing antibodies against SARS-CoV-2. This work demonstrated how detailed analysis of B-cell receptor repertoires can rapidly identify antibodies with potential applications in prevention and therapy.
Subsequent studies extended this work to questions of antibody breadth, immune memory, and antigenic diversity across SARS-CoV-2, HIV-1, and influenza viruses.
More recently, Kreer and colleagues have focused on humoral immunity against emerging influenza viruses. In a study published in Immunity in 2026, the team investigated antibody responses to H5N1 avian influenza viruses circulating in cattle and associated with human infections. They identified pre-existing cross-neutralizing antibodies in individuals without previous H5N1 exposure and isolated monoclonal antibodies capable of neutralizing the virus, providing important insights into pre-existing human immunity to emerging influenza strains.
His research has also extended beyond viral infections. Together with colleagues in Cologne, Kreer contributed to the development of human monoclonal antibodies targeting virulence mechanisms of Pseudomonas aeruginosa, exploring antibody-based approaches as potential alternatives to conventional antibiotics.
Scientific Career & Recognition
Kreer studied biochemistry at Goethe University Frankfurt and completed his PhD in Molecular Biomedicine at the Life and Medical Sciences Institute of the University of Bonn. In 2016, he joined the Laboratory of Experimental Immunology at the Institute of Virology at the University of Cologne, where he subsequently became Senior Scientist and scientific lead of an influenza A virus research team. In 2025, he completed his habilitation in Biochemistry at the University of Cologne with a thesis entitled “Optimized B-Cell Receptor Analyses to Develop Novel Therapy and Prevention Approaches against Infectious Diseases” and received the venia legendi in Biochemistry.
Since 2017, Kreer has been a Co-PI within the Cologne CRC 1310 “Predictability in Evolution,” where he contributes to a central project focused on developing technologies for massively parallel selection and evolution experiments. Since 2023, he has also been a scientific member of the Center for Predictive Analysis of Viral Evolution (Previr).
Kreer’s scientific work has received several distinctions and scholarships, including support from the “Stiftung Polytechnische Gesellschaft”, the “Studienstiftung des Deutschen Volkes” and the NRW International Graduate School LIMES Chemical Biology. In 2025, research to which he contributed on antibody-based approaches against Pseudomonas aeruginosa received the Galenus-von-Pergamon Award in the category Basic Research.
Current Research at the CMMC
In 2026, Kreer established the Research Group Immunodynamics and Molecular Evolution at the Institute of Virology and joined the CMMC as a Career Advancement Program (CAP) Group Leader.
Within CAP 45, the group investigates the reciprocal adaptation of humoral immunity and antigens, with current projects focusing particularly on influenza virus surface proteins and B-cell responses in pancreatic cancer. These complementary research directions allow the group to study principles of B-cell selection and antigen recognition across infectious disease and cancer.
The group’s integration into the CMMC strengthens its interdisciplinary links to complementary expertise in infection biology, immunology, cancer research, and translational medicine.